home All News open_in_new Full Article

Singapore’s Nanyang Biologics to list on Nasdaq amid Trump’s pharma tariffs.

Nanyang Biologics, a Singapore-based artificial intelligence drug discovery start-up, plans to list on the Nasdaq stock exchange in the first quarter of 2026 via a merger with a US-listed special-purpose acquisition company (SPAC), as US President Donald Trump vowed to impose hefty tariffs on pharmaceutical imports. “The US administration wants intellectual property owners to manufacture in the US, including drugs,” founder Roland Ong said on Monday. Nanyang Biologic’s latest initiative reflects...


today 8 d. ago attach_file Politics

attach_file Politics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 1034313129
Add Watch Country

arrow_drop_down